A Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Among participants who had a history of or were at risk for a first atherosclerotic cardiovascular disease event, treatment with the oral PCSK9 inhibitor enlicitide resulted in significantly lower LDL cholesterol levels than placebo at 24 weeks. (Funded by MSD [Rahway, NJ]; CORALreef Lipids ClinicalTrials.gov number, NCT05952856.).
Authors
- Lepor Ne
- Pengfei Zhu (ORCID: https://orcid.org/0000-0002-2315-3494)
- Kazuhisa Tsukamoto (ORCID: https://orcid.org/0000-0002-4166-6664)
- Elina Mikhailova
- Alberto Cadena (ORCID: https://orcid.org/0000-0001-8913-0319)
- A. Catapano
- Geraldine Mendizabal
- Dirk Blom
- Puja Banka
- Christie M. Ballantyne
- Ann Marie Navar
- Julio Nunez
- Susan Kourpanidis
- Wenjuan Zhang
- Min Zhuo
Institutions
- University of Cape Town (ZA)
- Universitat de València (ES)
- Baylor College of Medicine (US)
- University of Milan (IT)
- MSD (UK) Limited (United Kingdom) (GB)
- MultiMedica (IT)
- University of the Coast (CO)
- National Heart Institute (MY)
- University of Palermo (AR)
- Cedars-Sinai Smidt Heart Institute (US)
- MSCI (China) (CN)
- Mylan (Switzerland) (CH)
- The University of Texas Southwestern Medical Center (US)
- Teikyo University (JP)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2026-02-04
- DOI
- https://doi.org/10.1056/nejmoa2511002
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 156.59